https://www.marketscreener.com/quote/stock/SEAGEN-INC-10808/news/Seattle-Genetics-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-Tisotumab-Vedot-30844628/?utm_source=telegram&utm_medium=social&utm_campaign=share